CD8A and thyroid cancer: We conducted IHC for PD-L1 expression in tumor cells and CD8+ infiltration within the tumor to investigate tumor immune status, and investigated the presence of BRAFV600E mutation which was the most representative genetic mutation among thyroid cancer, using surgical specimens from initial surgeries of 33 patients with thyroid cancer in our department.